ADMA heads into its August 7 earnings print with short sellers quietly reducing exposure even as the stock trades at a steep discount to analyst targets.
Short interest is the primary tension here. At roughly 10% of the free float — about 23.8 million shares — ADMA carries a meaningful short position. Yet that figure has fallen around 1.8% over the past week and eased back after a sharp jump through mid-July, when it climbed from roughly 21.6 million to over 24.6 million shares before reversing. Borrow conditions are relaxed: availability is loose at over 1,300% — meaning roughly thirteen shares are available to borrow for every one already shorted — and cost to borrow has remained negligible at under 0.50%, a level unchanged for months. There is no squeeze pressure in the lending market. The stock has gained 6.3% over the past week and 3.9% in the last session alone, closing at $9.26, suggesting the covering activity may be adding to upward momentum rather than fighting it.
Options positioning reinforces the bullish lean. The put/call ratio has dropped to 0.31, well below its 20-day average of 0.35 and near its 52-week low of 0.23. That means call volume is dominating — investors are reaching for upside exposure rather than hedging against a miss. The z-score of -0.86 flags this as a below-average defensive setup, the opposite of what you typically see when traders are bracing for a difficult print.
The bull-versus-bear divide is sharpest on valuation. ADMA trades at $9.26 against a consensus price target of $17, implying roughly 84% upside — a gap that reflects how far the stock has fallen from earlier this year, when it was above $15. Mizuho trimmed its target to $17 from $20 on July 15 while keeping an Outperform rating, a move that acknowledged near-term headwinds without abandoning the long-term thesis. The broader analyst community has followed a similar pattern: Canaccord cut its target to $18 from $21 in May yet maintained a Buy. Bears point to the multiple downgrades in target prices across the board as evidence that execution risk remains real. Bulls counter with the EV/EBITDA multiple of just 6.2x and a forward P/E of 9.3x — undemanding for a biotech with a 74th-percentile ranking on forward EPS growth expectations. The founder and Vice Chairman added around 31,400 shares in late May at prices near $8, a signal that at least one insider viewed the pullback as overdone.
Tomorrow's print will test whether ADMA's commercial execution and margin trajectory can justify closing any part of the gap between where the stock trades and where analysts still believe it belongs.
See the live data behind this article on ORTEX.
Open ADMA on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
